NCI-2022-03773

Phase 1/2, Safety Confirmation and Double-blind, Placebo-controlled, Randomized Study of Relatlimab in Combination with Nivolumab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106)

This is a safety and efficacy study to evaluate a drug called relatlimab in combination with two other drugs, nivolumab and bevacizumab, for the treatment of people with advanced or metastatic hepatocellular carcinoma, a type of liver cancer. The main goal is to confirm that the drug combination is safe for people to take. Neither the patients nor the doctors will know who is taking the actual drug combination and who is taking a placebo. Patients will be randomly assigned to either the drug combination group or the placebo group. The investigational drug being studied is relatlimab, an immunotherapy drug that helps the immune system attack cancer cells. Nivolumab is another immunotherapy drug already approved for some cancers. Bevacizumab is a drug that blocks the growth of new blood vessels that tumors need to grow. The study is only for people who have not previously been treated for their hepatocellular carcinoma.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

Metastatic: cancer that has spread from its original location or organ to other parts of the body.

Placebo: A placebo is a substance or treatment that has no active medical properties but is given to a patient as if it were a real medication or treatment. It is often used in medical research to compare the effects of a new drug or treatment with the effects of no treatment at all. The idea is to see if the new drug or treatment is genuinely effective by comparing how patients who receive the real treatment fare compared to those who receive the placebo

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05337137

NCI-2022-03773

Clinical Trial Site: Einstein

To see all available clinical trials click here.